Nova Medical Supplies ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  16.2% 20.1% 15.0% 11.9% 32.4%  
Credit score (0-100)  12 6 13 19 0  
Credit rating  BB B BB BB C  
Credit limit (kDKK)  0.0 -0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  0 0 0 0 0  
Gross profit  -13.8 -24.9 -3.7 60.2 301  
EBITDA  -13.8 -24.9 -3.7 60.2 301  
EBIT  -13.8 -24.9 -3.7 60.2 301  
Pre-tax profit (PTP)  -13.8 -24.9 -5.8 96.0 -57.2  
Net earnings  -7.6 -19.5 -4.8 74.8 -65.7  
Pre-tax profit without non-rec. items  -13.8 -24.9 -5.8 96.0 -57.2  

 
See the entire income statement

Balance sheet (kDKK) 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  414 8.9 7.2 82.0 16.3  
Interest-bearing liabilities  0.0 0.0 58.0 2.0 1.0  
Balance sheet total (assets)  421 8.9 203 1,340 17.8  

Net Debt  -85.1 -0.4 56.6 -1,191 0.0  
 
See the entire balance sheet

Volume 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -13.8 -24.9 -3.7 60.2 301  
Gross profit growth  0.0% -80.9% 85.1% 0.0% 399.4%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  421 9 203 1,340 18  
Balance sheet change%  -80.7% -97.9% 2,179.4% 561.1% -98.7%  
Added value  -13.8 -24.9 -3.7 60.2 300.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 -2.0 -3.0 1.0 2.0  

Profitability 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -1.1% -11.6% 7.5% 12.8% 50.0%  
ROI %  -1.3% -11.8% 21.3% 132.9% 670.8%  
ROE %  -0.7% -9.2% -60.1% 167.8% -133.8%  

Solidity 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Equity ratio %  98.5% 100.0% 3.5% 6.1% 91.6%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  617.1% 1.6% -1,527.4% -1,977.1% 0.0%  
Gearing %  0.0% 0.0% 806.7% 2.4% 6.2%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 47.2% 10.1% 26,561.0%  

Liquidity 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Quick Ratio  67.3 0.0 1.0 1.1 11.8  
Current Ratio  67.3 0.0 1.0 1.1 11.8  
Cash and cash equivalent  85.1 0.4 1.3 1,192.6 1.0  

Capital use efficiency 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  414.3 8.9 7.2 82.0 16.3  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0